Larissa Neto Espíndola

Larissa Neto Espíndola

Auto-generated profile, based on publicly available information

Larissa Neto Espíndola

Hospital Santa Izabel, Brasil; Hospital Municipal de Salvador, Brasil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
GOGlaucia Oliveira
Glaucia Oliveira
MAMaria Cristina Costa de Almeida
Maria Cristina Costa de Almeida
CACarolina María Artucio Arcelus
Carolina María Artucio Arcelus
LELarissa Neto Espíndola
Larissa Neto Espíndola
MRMaria Alayde Mendonça Rivera
Maria Alayde Mendonça Rivera
MWMaria Celeste Osorio Wender
Maria Celeste Osorio Wender
1. Introdução Após a publicação dos resultados de ensaio clínico realizado pelo Women’s Health Initiative (WHI) em 2002, demonstrando que há mais riscos do que benefícios para a saúde feminina com a utilização de estrogênio (isolado ou combinado a progestagênio) para o controle dos sinais e sintomas da menopausa, houve uma diminuição progressiva e sustentada na prescrição desses medicamentos.– Nos Estados Unidos, havia ocorrido um aumento de prescrições da terapia hormonal da menopausa (THM) de 16 milhões em 1966 para [...] 1. Introdução Após a publicação dos resultados de ensaio clínico realizado pelo Women’s Health Initiative (WHI) em 2002, demonstrando que há mais riscos do que benefícios para a saúde feminina com a utilização de estrogênio (isolado ou combinado a progestagênio) para o controle dos sinais e sintomas da menopausa, houve uma diminuição progressiva e sustentada na prescrição desses medicamentos.– Nos Estados Unidos, havia ocorrido um aumento de prescrições da terapia hormonal da menopausa (THM) de 16 milhões em 1966 para

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
GOGlaucia Oliveira
Glaucia Oliveira
MAMaria Cristina Costa de Almeida
Maria Cristina Costa de Almeida
CACarolina María Artucio Arcelus
Carolina María Artucio Arcelus
LELarissa Neto Espíndola
Larissa Neto Espíndola
MRMaria Alayde Mendonça Rivera
Maria Alayde Mendonça Rivera
MWMaria Celeste Osorio Wender
Maria Celeste Osorio Wender
1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In the United States, there was an increase in the prescription of menopausal hormone therapy (MHT) from 16 million in 1966 to 90 million in 1999,– [...] 1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In the United States, there was an increase in the prescription of menopausal hormone therapy (MHT) from 16 million in 1966 to 90 million in 1999,–

7 October 2024 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
GOGlaucia Oliveira
Glaucia Oliveira
MAMaria Cristina Costa de Almeida
Maria Cristina Costa de Almeida
CACarolina María Artucio Arcelus
Carolina María Artucio Arcelus
LELarissa Espíndola
Larissa Espíndola
MRMaria Alayde Mendonça Rivera
Maria Alayde Mendonça Rivera
MWMaria Celeste Osorio Wender
Maria Celeste Osorio Wender
1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In […] 1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In […]

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
LELarissa Neto Espíndola
Larissa Neto Espíndola
AGAlexandra Maria Monteiro Grisolia
Alexandra Maria Monteiro Grisolia
GOGlaucia Oliveira
Glaucia Oliveira
Over the last years, advances in digital technology (DT) have revolutionized various sectors, and health is not an exception. Digital tools including monitoring devices, telemedicine platforms and even wearables have enabled individuals to be responsible for their self-care. These technological innovations are particularly transformative for women, contributing to overcome a historical barrier to access to health care (now in the palm of their hands), and also to promote health and prevention of disease progression. The recent World Health Organization report [...] Over the last years, advances in digital technology (DT) have revolutionized various sectors, and health is not an exception. Digital tools including monitoring devices, telemedicine platforms and even wearables have enabled individuals to be responsible for their self-care. These technological innovations are particularly transformative for women, contributing to overcome a historical barrier to access to health care (now in the palm of their hands), and also to promote health and prevention of disease progression. The recent World Health Organization report

12 August 2024 in International Journal of Cardiovascular Sciences
Verified
Journal Article
Open access
PDF file
LELarissa Neto Espíndola
Larissa Neto Espíndola
GOGlaucia Oliveira
Glaucia Oliveira
CFCláudia Maria Vilas Freire
Cláudia Maria Vilas Freire
MCMarildes Luiza de Castro
Marildes Luiza de Castro
MAMaria Cristina Costa de Almeida
Maria Cristina Costa de Almeida
Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy that affects the heart mostly in two forms: immunoglobulin light chain amyloidosis (AL-CM) and transthyretin amyloidosis. Transthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects the elderly population, mainly men (about 70-80%), and usually manifests with symptoms of heart failure (HF). Despite technological advances in medicine, CA is still an underdiagnosed condition, especially in women, partly due to the known male predominance and high level of suspicion required for diagnosis. It is important to remember [...] Abstract Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy that affects the heart mostly in two forms: immunoglobulin light chain amyloidosis (AL-CM) and transthyretin amyloidosis. Transthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects the elderly population, mainly men (about 70-80%), and usually manifests with symptoms of heart failure (HF). Despite technological advances in medicine, CA is still an underdiagnosed condition, especially in women, partly due to the known male predominance and high level of suspicion required for diagnosis. It is important to remember

29 August 2023 in International Journal of Cardiovascular Sciences
Verified
Journal Article
Open access
PDF file
MAMaria Cristina Costa de Almeida
Maria Cristina Costa de Almeida
MCMarildes Luiza Castro
Marildes Luiza Castro
LELarissa Espíndola
Larissa Espíndola
LALuciana Nicolau Aranha
Luciana Nicolau Aranha
TSThaís Salim
Thaís Salim
GOGlaucia Oliveira
Glaucia Oliveira
Metabolic syndrome (MetS) is increasing at epidemic proportions worldwide. MetS and its components are frequent among Brazilian women (41.8%). Women are affected by changes in adipose tissue distribution, lipid profile, insulin resistance (IR), and vascular remodeling during their lives. These changes result from the lack of estrogen after menopause. There have been various attempts to propose a uniform origin for the clustering of the MetS components, including genetics, IR, obesity, lifestyle, sleep disturbances, inflammation, fetal and neonatal programming, and [...] Abstract Metabolic syndrome (MetS) is increasing at epidemic proportions worldwide. MetS and its components are frequent among Brazilian women (41.8%). Women are affected by changes in adipose tissue distribution, lipid profile, insulin resistance (IR), and vascular remodeling during their lives. These changes result from the lack of estrogen after menopause. There have been various attempts to propose a uniform origin for the clustering of the MetS components, including genetics, IR, obesity, lifestyle, sleep disturbances, inflammation, fetal and neonatal programming, and